Overview
Surgeon's Perspective: Management of Early Stage NSCLC
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This activity is intended for oncologists, pathologists, pulmonologists, and other clinicians involved in the treatment of non-small cell lung cancer (NSCLC). The forum will also serve the interests of patients, caregivers, case managers, and payor groups.
At the conclusion of this program, participants should be able to:
- Incorporate findings from histopathology and mutation analyses into safe and effective treatment strategies for NSCLC
- Apply best evidence for maintenance therapy with novel chemotherapeutic and molecularly-targeted agents for patients with advanced NSCLC
- Select appropriate targeted agents for personalized treatment of patients with nonsquamous NSCLC
- Collaborate with other specialists to improve the accuracy of diagnosis and optimize treatment options for patients with NSCLC
Jointly Sponsored by Indiana University School of Medicine and The Academy for Continued Healthcare Learning
Supported by an educational grant from Lilly USA, LLC. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
| Course Director | |
 | Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Department of Hematology and Medical Oncology Winship Cancer Institute of Emory University Atlanta, GA |
| Faculty | |
 | Joshua P. Cohen, PhD Senior Research Fellow Tufts University Center for the Study of Drug Development Boston, MA |
 | Fred R. Hirsch, MD, PhD Professor of Medicine and Pathology University of Colorado Cancer Center Aurora, CO |
 | Lorraine G. Monroe, RN Co-Founder, Lung Cancer Foundation of America Patient Advocate Bowling Green, KY |
 | Joe B. Putnam, Jr., MD, FACS Professor and Chair of Thoracic Surgery Ingram Professor of Surgery Professor of Biomedical Informatics Vanderbilt-Ingram Cancer Center Nashville, TN |
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Indiana University School of Medicine (IUSM) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an IUSM-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Please Note:
While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.
This activity is available from 6/22/2012 through 6/21/2013. (1 year)
Suresh S. Ramalingam, MD, (Chair) Type of financial relationships:
Consulting Agreements: Abbott, Astellas, Aveo, Boehringer-Ingelheim, Lilly, Genentech, Pfizer
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
Joshua P. Cohen, PhD, (Faculty) Type of financial relationship: None
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
Fred R. Hirsh, MD, PhD, (Chair) Type of financial relationships:
Speakers Bureau: Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Genentech, OSI Pharmaceutical, Roche, Pfizer
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
Lorraine G. Monroe, RN (Faculty) Type of financial relationship: None
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
Joe B. Putnam, Jr., MD, FACS, (Chair) Type of financial relationship: None
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
Please Note:
While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.
This activity is available from 6/22/2012 through 6/21/2013. (1 year)
Suresh S. Ramalingam, MD, (Chair) Type of financial relationships:
Consulting Agreements: Abbott, Astellas, Aveo, Boehringer-Ingelheim, Lilly, Genentech, Pfizer
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
Joshua P. Cohen, PhD, (Faculty) Type of financial relationship: None
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
Fred R. Hirsh, MD, PhD, (Chair) Type of financial relationships:
Speakers Bureau: Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Genentech, OSI Pharmaceutical, Roche, Pfizer
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
Lorraine G. Monroe, RN (Faculty) Type of financial relationship: None
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
Joe B. Putnam, Jr., MD, FACS, (Chair) Type of financial relationship: None
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
The Academy for Continued Healthcare Learning (ACHL), staff members, Indiana University School of Medicine, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations.
It has been determined that this online activity can be completed in 0.75 hour. The participant should complete the preactivity survey, review the learning objectives and faculty disclosures, view the online Webcast, reflect on the content, and complete the postactivity survey. A certificate of credit will be immediately available when the completed postactivity survey and evaluation are submitted online. There is no fee to participate in the activity or for the generation of the certificate.
| Hardware and Software Requirements |
|
 | Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. |
